MicroRNAs as Potential Biomarkers for Diagnosing Cancers of Central Nervous System: a Meta-analysis

Molecular Neurobiology

Volumn 51, Issue 3, 2015, Pages 1452-1461

  Wei, Dong ^a   Wan, Qun ^a,b   Li, Li ^a   Jin, Haifeng ^a,c   Liu, Yonghong ^a   Wang, Yangang ^d   Zhang, Guangyun ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b Chinese PLA 254 Hospital   (China)

^c BETHUNE INTERNATIONAL PEACE HOSPITAL   (China)

^d FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Central nervous system cancers; Diagnosis; Meta analysis; MicroRNAs

Indexed keywords

MICRORNA; TUMOR MARKER;

CENTRAL NERVOUS SYSTEM NEOPLASMS; GENETICS; HUMAN; META ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

BIOMARKERS, TUMOR; CENTRAL NERVOUS SYSTEM NEOPLASMS; HUMANS; MICRORNAS; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 84939897109     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-014-8822-6     Document Type: Article

References (45)

1. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55(2):74–108
2. Turner JD, Williamson R, Almefty KK, Nakaji P, Porter R, Tse V, Kalani MY (2010) The many roles of microRNAs in brain tumor biology. Neurosurg Focus. doi:10.3171/2009.10.FOCUS09207
3. Schafer N, Glas M, Herrlinger U (2012) Primary CNS lymphoma: a clinician’s guide. Expert Rev Neurother 12(10):1197–1206
4. Pels H, Schmidt-Wolf IG, Glasmacher A, Schulz H, Engert A, Diehl V, Zellner A, Schackert G, Reichmann H, Kroschinsky F, Vogt-Schaden M, Egerer G, Bode U, Schaller C, Deckert M, Fimmers R, Helmstaedter C, Atasoy A, Klockgether T, Schlegel U (2003) Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol Off J Am Soc Clin Oncol 21(24):4489–4495
5. Tran B, Rosenthal MA (2010) Survival comparison between glioblastoma multiforme and other incurable cancers. J Clin Neurosci Off J Neurosurg Soc Australas 17(4):417–421
6. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5):459–466
7. Ilhan-Mutlu A, Wagner L, Preusser M (2013) Circulating biomarkers of CNS tumors: an update. Biomark Med 7(2):267–285
8. Roth P, Wischhusen J, Happold C, Chandran PA, Hofer S, Eisele G, Weller M, Keller A (2011) A specific miRNA signature in the peripheral blood of glioblastoma patients. J Neurochem 118(3):449–457
9. Zheng PP, Hop WC, Sillevis Smitt PA, van den Bent MJ, Avezaat CJ, Luider TM, Kros JM (2005) Low-molecular weight caldesmon as a potential serum marker for glioma. Clin Cancer Res Off J Am Assoc Cancer Res 11(12):4388–4392
10. Fukuda ME, Iwadate Y, Machida T, Hiwasa T, Nimura Y, Nagai Y, Takiguchi M, Tanzawa H, Yamaura A, Seki N (2005) Cathepsin D is a potential serum marker for poor prognosis in glioma patients. Cancer Res 65(12):5190–5194
11. Baraniskin A, Kuhnhenn J, Schlegel U, Chan A, Deckert M, Gold R, Maghnouj A, Zollner H, Reinacher-Schick A, Schmiegel W, Hahn SA, Schroers R (2011) Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system. Blood 117(11):3140–3146
12. Schroers R, Baraniskin A, Heute C, Vorgerd M, Brunn A, Kuhnhenn J, Kowoll A, Alekseyev A, Schmiegel W, Schlegel U, Deckert M, Pels H (2010) Diagnosis of leptomeningeal disease in diffuse large B-cell lymphomas of the central nervous system by flow cytometry and cytopathology. Eur J Haematol 85(6):520–528
13. Kiewe P, Fischer L, Martus P, Thiel E, Korfel A (2010) Meningeal dissemination in primary CNS lymphoma: diagnosis, treatment, and survival in a large monocenter cohort. Neuro-Oncology 12(4):409–417
14. Fischer L, Martus P, Weller M, Klasen HA, Rohden B, Roth A, Storek B, Hummel M, Nagele T, Thiel E, Korfel A (2008) Meningeal dissemination in primary CNS lymphoma: prospective evaluation of 282 patients. Neurology 71(14):1102–1108. doi:10.1212/01.wnl.0000326958.52546.f5
15. Roy S, Josephson SA, Fridlyand J, Karch J, Kadoch C, Karrim J, Damon L, Treseler P, Kunwar S, Shuman MA, Jones T, Becker CH, Schulman H, Rubenstein JL (2008) Protein biomarker identification in the CSF of patients with CNS lymphoma. J Clin Oncol Off J Am Soc Clin Oncol 26(1):96–105
16. Kersten MJ, Evers LM, Dellemijn PL, van den Berg H, Portegies P, Hintzen RQ, van Lier RA, von dem Borne AE, van Oers RH (1996) Elevation of cerebrospinal fluid soluble CD27 levels in patients with meningeal localization of lymphoid malignancies. Blood 87(5):1985–1989
17. Schroers R, Baraniskin A, Heute C, Kuhnhenn J, Alekseyev A, Schmiegel W, Schlegel U, Pels HJ (2010) Detection of free immunoglobulin light chains in cerebrospinal fluids of patients with central nervous system lymphomas. Eur J Haematol 85(3):236–242
18. Huang Y, Zou Q, Song H, Song F, Wang L, Zhang G, Shen X (2010) A study of miRNAs targets prediction and experimental validation. Protein Cell 1(11):979–986
19. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116(2):281–297
20. Li M, Li J, Ding X, He M, Cheng SY (2010) microRNA and cancer. AAPS J 12(3):309–317
21. Zhang B, Pan X, Cobb GP, Anderson TA (2007) microRNAs as oncogenes and tumor suppressors. Dev Biol 302(1):1–12
22. Calin GA, Croce CM (2006) MicroRNA signatures in human cancers. Nat Rev Cancer 6(11):857–866
23. Thapa DR, Hussain SK, Tran WC, D’Souza G, Bream JH, Achenback CJ, Ayyavoo V, Detels R, Martinez-Maza O (2014) Serum micrornas in HIV-infected individuals as pre-diagnosis biomarkers for aids-related non-hodgkin lymphomas (aids-NHL). J Acquir Immune Defic Syndr 66(2):229–237
24. Mao X, Sun Y, Tang J (2014) Serum miR-21 is a diagnostic and prognostic marker of primary central nervous system lymphoma. Neurol Sci 35(2):233–238
25. Baraniskin A, Kuhnhenn J, Schlegel U, Maghnouj A, Zollner H, Schmiegel W, Hahn S, Schroers R (2012) Identification of microRNAs in the cerebrospinal fluid as biomarker for the diagnosis of glioma. Neuro-Oncology 14(1):29–33
26. Yang C, Wang C, Chen X, Chen S, Zhang Y, Zhi F, Wang J, Li L, Zhou X, Li N, Pan H, Zhang J, Zen K, Zhang CY, Zhang C (2013) Identification of seven serum microRNAs from a genome-wide serum microRNA expression profile as potential noninvasive biomarkers for malignant astrocytomas. Int J Cancer J Int Cancer 132(1):116–127
27. Kosaka N, Iguchi H, Ochiya T (2010) Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci 101(10):2087–2092
28. Hu Z, Chen X, Zhao Y, Tian T, Jin G, Shu Y, Chen Y, Xu L, Zen K, Zhang C, Shen H (2010) Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol 28(10):1721–1726
29. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, Li Q, Li X, Wang W, Zhang Y, Wang J, Jiang X, Xiang Y, Xu C, Zheng P, Zhang J, Li R, Zhang H, Shang X, Gong T, Ning G, Wang J, Zen K, Zhang J, Zhang CY (2008) Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18(10):997–1006
30. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, Leeflang MM, Sterne JA, Bossuyt PM (2011) QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 155(8):529–536
31. Mitchell AJ, Vaze A, Rao S (2009) Clinical diagnosis of depression in primary care: a meta-analysis. Lancet 374(9690):609–619
32. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557–560
33. Dinnes J, Deeks J, Kirby J, Roderick P (2005) A methodological review of how heterogeneity has been examined in systematic reviews of diagnostic test accuracy. Health Technol Assess 9(12):1–113, iii
34. Zamora J, Abraira V, Muriel A, Khan K, Coomarasamy A (2006) Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol. doi:10.1186/1471-2288-6-31
35. Sterne JA, Gavaghan D, Egger M (2000) Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol 53(11):1119–1129
36. Weller M, Martus P, Roth P, Thiel E, Korfel A (2012) Surgery for primary CNS lymphoma? Challenging a paradigm. Neuro-Oncology 14(12):1481–1484
37. Nishikawa R (2012) Resection of PCNSL, if safely possible, seems to be better than biopsy: challenging a paradigm? Neuro-Oncology 14(12):1423
38. Yu DC, Li QG, Ding XW, Ding YT (2011) Circulating MicroRNAs: Potential Biomarkers for Cancer. Int J Mol Sci 12(3):2055–2063
39. Puerta-Gil P, Garcia-Baquero R, Jia AY, Ocana S, Alvarez-Mugica M, Alvarez-Ossorio JL, Cordon-Cardo C, Cava F, Sanchez-Carbayo M (2012) miR-143, miR-222, and miR-452 are useful as tumor stratification and noninvasive diagnostic biomarkers for bladder cancer. Am J Pathol 180(5):1808–1815
40. Piepoli A, Tavano F, Copetti M, Mazza T, Palumbo O, Panza A, di Mola FF, Pazienza V, Mazzoccoli G, Biscaglia G, Gentile A, Mastrodonato N, Carella M, Pellegrini F, di Sebastiano P, Andriulli A (2012) Mirna expression profiles identify drivers in colorectal and pancreatic cancers. PLoS One 7(3):e33663
41. Fiorucci G, Chiantore MV, Mangino G, Percario ZA, Affabris E, Romeo G (2012) Cancer regulator microRNA: potential relevance in diagnosis, prognosis and treatment of cancer. Curr Med Chem 19(4):461–474
42. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O’Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 105(30):10513–10518
43. Reddy SD, Gajula RP, Pakala SB, Kumar R (2010) MicroRNAs and cancer therapy: the next wave or here to stay? Cancer Biol Ther 9(7):479–482
44. Wiemer EA (2007) The role of microRNAs in cancer: no small matter. Eur J Cancer (Oxford, England: 1990) 43(10):1529–1544
45. Jin XF, Wu N, Wang L, Li J (2013) Circulating microRNAs: a novel class of potential biomarkers for diagnosing and prognosing central nervous system diseases. Cell Mol Neurobiol 33(5):601–613